Therapeutics

Barry Potter (Inventor), James Dowden (Inventor), Antony Galione (Inventor)

Research output: Patent

Abstract

The present invention relates to the use of a compound of formula (I); wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.
Original languageEnglish
Patent numberWO2005054198 (A2)
IPCA61K31/4425
Publication statusPublished - 16 Jun 2005

Fingerprint

Calcium Signaling
Insulin-Secreting Cells
Therapeutics
Phagocytes
T-Lymphocytes
Brain
Calcium
Salts
NAADP

Cite this

Potter, B., Dowden, J., & Galione, A. (2005). IPC No. A61K31/4425. Therapeutics. (Patent No. WO2005054198 (A2)).

Therapeutics. / Potter, Barry (Inventor); Dowden, James (Inventor); Galione, Antony (Inventor).

IPC No.: A61K31/4425. Patent No.: WO2005054198 (A2).

Research output: Patent

Potter, B, Dowden, J & Galione, A 2005, Therapeutics, Patent No. WO2005054198 (A2), IPC No. A61K31/4425.
Potter B, Dowden J, Galione A, inventors. Therapeutics. A61K31/4425. 2005 Jun 16.
Potter, Barry (Inventor) ; Dowden, James (Inventor) ; Galione, Antony (Inventor). / Therapeutics. IPC No.: A61K31/4425. Patent No.: WO2005054198 (A2).
@misc{88a70978f2464be2a02b2b5a09f58370,
title = "Therapeutics",
abstract = "The present invention relates to the use of a compound of formula (I); wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.",
author = "Barry Potter and James Dowden and Antony Galione",
year = "2005",
month = "6",
day = "16",
language = "English",
type = "Patent",
note = "WO2005054198 (A2); A61K31/4425",

}

TY - PAT

T1 - Therapeutics

AU - Potter, Barry

AU - Dowden, James

AU - Galione, Antony

PY - 2005/6/16

Y1 - 2005/6/16

N2 - The present invention relates to the use of a compound of formula (I); wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.

AB - The present invention relates to the use of a compound of formula (I); wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.

M3 - Patent

M1 - WO2005054198 (A2)

ER -